US 12,240,908 B2
N-terminal scFv multispecific binding molecules
Yang Shen, Scarsdale, NY (US); Ann-Hwee Lee, Ardsley, NY (US); Yan Yang, Mamaroneck, NY (US); and Chia-Yang Lin, Scarsdale, NY (US)
Assigned to Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US)
Filed by Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US)
Filed on Apr. 22, 2022, as Appl. No. 17/726,950.
Application 17/726,950 is a continuation of application No. PCT/US2020/058798, filed on Nov. 4, 2020.
Claims priority of provisional application 62/930,916, filed on Nov. 5, 2019.
Prior Publication US 2022/0251220 A1, Aug. 11, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01); C07K 16/40 (2006.01)
CPC C07K 16/2863 (2013.01) [C07K 16/2896 (2013.01); C07K 16/40 (2013.01); C07K 2317/31 (2013.01); C07K 2317/35 (2013.01); C07K 2317/52 (2013.01); C07K 2317/522 (2013.01); C07K 2317/54 (2013.01); C07K 2317/55 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/92 (2013.01)] 10 Claims
 
1. A trivalent multispecific binding molecule (MBM), comprising:
(a) a first polypeptide chain comprising in an N-to C-terminal orientation:
(i) an scFv comprising means for binding to human amyloid precursor-like protein 2 (APLP2);
(ii) a linker;
(iii) a first heavy chain region of a first Fab comprising means for binding to human fibroblast growth factor receptor 3 (FGFR3); and
(iv) a first Fc domain; and
(b) a second polypeptide chain comprising, in an N-to C-terminal orientation:
(i) a second heavy chain region of a second Fab comprising means for binding to human FGFR3; and
(ii) a second Fc domain capable of heterodimerizing with the first Fc domain to form an Fc heterodimer;
(c) a third polypeptide chain comprising a first light chain that pairs with the first heavy chain region to form the first Fab; and
(d) a fourth polypeptide chain comprising a second light chain that pairs with the second heavy chain region to form the second Fab.